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Availability, use, and affordability of
medicines in urban China under universal
health coverage: an empirical study in
Hangzhou and Baoji
Yunyu Huang1,2,3†, Youfen Jiang1†, Luying Zhang1†, Wenhui Mao1, Job F. M. van Boven2,
Maarten J. Postma2,3,4 and Wen Chen1*
Abstract
Background: This study aimed to examine the availability, use, and affordability of medicines in urban China
following the 2009 Health Care System Reform that included implementation of universal health coverage (UHC).
Methods: This longitudinal study was performed in Hangzhou (high income, eastern China) and Baoji (lower income,
western China). Five yearly household surveys were conducted (one each year from 2009 to 2013) to evaluate the impact
of UHC on medicines use and expenditure, and a health facility survey was conducted in 2013 to evaluate availability of
medicines. A cohort of over 800 households in Hangzhou and Baoji was established in 2009, and 20 hospitals were
included in the health facility survey. Medicines use was determined using data from health facility and household surveys.
An average, two-week out-of-pocket medicines expenditure was calculated to assess the affordability of medicines.
Results: The number of medicines stocked in primary health facilities in Hangzhou decreased, while the number in Baoji
increased. In Baoji, patients usually chose a pharmacy to buy medicines directly, despite the 48.2% increased availability of
essential medicines in primary health care centers. The majority of survey respondents stated that their medicines need
was basically met; however, medicines cost still accounted for a major part of their health expenditure. Medicines
expenditure showed an increasing trend from 2009 to 2013. The average annual growth rate of household overall medical
expenditure was significantly higher than that for household non-food consumption expenditure.
Conclusions: Following China’s Health Care System Reform and implementation of UHC, availability and use of medicines
has improved in urban areas. However, the affordability of medicines is still a concern.
Keywords: Medicines, Availability, Use, Affordability, Urban China, Universal health coverage
Background
In 2010, the World Health Organization (WHO) devel-
oped an operational guide for achieving universal health
coverage (UHC) [1]. One of the goals of UHC is to
ensure that individuals are able to afford health services
and medicines. China is one of the low- and middle-
income countries that has developed and implemented
national strategies for UHC [2]. Following China’s Health
Care System Reform in 2009 [3], UHC (comprising three
main health insurance schemes) was preliminarily estab-
lished to cover both urban and rural populations in China.
The collective population covered by the rural New
Cooperative Medical Scheme (NCMS), Urban Employee
Basic Medical Insurance (UEBMI), and Urban Resident
Basic Medical Insurance (URBMI) was > 98% of the total
population of China in 2013 [4]. By expanding the UHC
over the past decade, access to health care in China has
been substantially improved [5].
Despite the broad population coverage, UHC in China
is still in its primary stage [6]. Beneficiaries of these basic
medical insurance schemes still have to pay a substantial
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proportion of health care expenditure as an out-of-
pocket (OOP) expense [7, 8]. In 2010, expenditure on
medicines in China accounted for > 40% of the total
health expenditure [9]. One of the main reasons for
this large percentage was the over-prescription and
overuse of medicines (including antibiotics) in health facil-
ities in order to generate greater revenues. Notably, this
phenomenon mainly appeared after the marketization of
the health care system during the implementation of the
“reform and opening-up” program of economic reforms in
1978 in China [10, 11].
Noting that there were problems, the Chinese govern-
ment began to develop appropriate policies and mecha-
nisms through the implementation of health insurance
schemes, the aim of which was to tackle overuse of
medicines and control the rapid rise of health care costs
— especially OOP payments [12, 13]. The health insur-
ance system has acted as a third-party service purchaser,
to ensure that service providers deliver high-quality
services in an effective and efficient way.
The Health Care System Reform was a milestone in im-
proving the health system in China. It was in 2009, under
the reform, that the URBMI began to reimburse out-
patient services (including medication) for the remaining
population (i.e. those without coverage in the previous in-
surance system) in urban areas — largely comprising un-
employed adults, the elderly, and children [14]. In
addition, an essential drug policy was implemented that
established a system of coverage for the main drugs
needed by the public. These policy adjustments resulted
in significant improvements in access to medicines, and
reduced the financial burden placed on the service users
— particularly those in low-income populations.
In recent decades, the availability, use, and affordabil-
ity of (essential) medicines in China have been the sub-
jects of extensive research [15–20], and the development
of China’s essential medicines policies following the
implementation of the Health Care System Reform in
2009 reviewed and analyzed in literature [21]. Findings
of these studies/analyses showed that hospitals paid little
attention to China’s National Essential Medicine List
(NEML) in their decisions to purchase and stock essen-
tial medicines, and that there were worrying decreases
in the availability of the lowest-price generic medicines
in both the public hospitals and private pharmacies.
Other studies have assessed medicine price, availability,
and affordability using a methodology developed by the
WHO and Health Action International [22–26]. The
results of these studies showed that treating common
diseases with low-price generics was generally affordable
in China, whereas treatment with innovator brands was
less affordable — especially for low-income populations.
In addition, prescribing/use of essential medicines was
frequently inappropriate. However, there is paucity of
policy-oriented research on use of medicines in relation
to design and implementation of specific national health
insurance schemes across different socio-economic set-
tings (e.g. high income eastern China versus lower income
western China). One available study evaluated the impact
of the Shenzhen labor health insurance scheme on access
to essential medicines among migrant workers in 2007
[27]. However, the sample in this study was restricted to a
local insurance scheme, which hampered extrapolation to
national basic insurance coverage. Research on medicine
use, availability, and affordability in relation to the national
health insurance system following the 2009 reform could
help to inform strategy and policy adjustments and im-
prove affordable use of medicines under the current UHC
in China.
This study aimed to examine the availability, use, and
affordability of medicines in urban China after the
implementation of China’s Health Care System Reform
in 2009. In particular, the differences in medicine use
and beneficiaries’ financial burden under the two major
national urban basic medical insurance schemes (UEBMI
and URBMI) were evaluated by comparing eastern
China (high income, more health facilities) and western
China (lower income, fewer health facilities).
Methods
Study design and setting
This study was a retrospective study that consisted of
policy situational analysis, household surveys, and health
facility survey in Hangzhou and Baoji.
Hangzhou (Zhejiang province) and Baoji (Shaanxi prov-
ince) were selected as the sample cities based on their
socio-economic level and health-system development, and
as being representative of different regions in China. Both
cities were included in the first batch of pilot cities imple-
menting URBMI in 2009. These two cities were previously
designated as Chinese national healthy cities, a national
award to commend municipalities for their outstanding
construction of health systems, which ensured that the
surveys were efficiently conducted and the collected data
were of good quality. In addition, the differences in socio-
economic development (Table 1) and design of health in-
surance schemes in the two sample cities were apparent
(Hangzhou: higher income, more health facilities; Baoji:
lower income, fewer health facilities), which made these
two cities typical urban representatives of eastern and
western China that could be used to compare the regional
UHC systems and outcomes of medicine supply and use.
Definitions developed by the WHO were taken as
reference to create the measures that allowed us to assess
medicines availability, use, and affordability in China. Avail-
ability of medicines is defined by the WHO Health and
Human Rights report, which states that medicines have to
be available in sufficient quantity in public health and
Huang et al. BMC Health Services Research  (2018) 18:218 Page 2 of 10
health care facilities [28]. The health facility survey was
designed to determine the number of different medicines in
stock in order to assess availability. Medicines use in this
study was defined as the medicines taken or prescribed dur-
ing patients’ health services, and patients’ perceptions of
medicines use in daily life. Affordability of medicines was
measured as the medicines expenditure and the ratio of
medicines expenditure to total household resources [29].
The household surveys were conducted in the two sample
cities, collecting residents’ data that allowed us to deter-
mine medicines use and affordability.
Situational analysis
Relevant secondary data/information (including policy
guidelines on insurance benefit packages, medicines
policy and regulations, and local implementation
plans related to UEBMI and URBMI in the two sam-
ple cities, etc.) were searched for and collected. Based
on these materials, a situational analysis was per-
formed to establish the basic background of the
health insurance schemes and medicine policies in
urban China, and in the two sample cities in particu-
lar. The content in the documents in written Chinese
was translated by researchers from School of Public
Health of the Fudan University in Shanghai, China
(including the first and second authors of the present
study). The translation referred to existing terms from
literature [30–32] and was approved by reviewers
from the funding organization (WHO).
Household surveys
A cohort of over 800 households in Hangzhou and Baoji
was established. A sample size of 2435 people was esti-
mated using the hospitalization rate of 6.8% (obtained
from the 4th National Health Services Survey in China)
in order to ensure the power of statistical analyses for
health-visit data. The sample size was calculated using
the following formula [33]:
n ¼ Z2P 1‐Pð Þ=δ2
Based on a degree of confidence of 95%, the statistic Z
was set to 1.96. The P was set as the hospitalization rate
of 6.8%, and the allowable error δ was set to 0.01. Based
on the average number of three people per household, 800
households were designated to be investigated. Five
household surveys were conducted (one each year from
2009 to 2013 in July/August to a total of five) to examine
use of and expenditure related to health care services for
urban residents. The survey used a structured question-
naire consisting of 7 sections: 1.) demographic informa-
tion (e.g. age, sex, education, health insurance plan, etc.);
2.) perceived health needs (recent and chronic illness); 3.)
service and medicines use during the past two weeks; 4.)
costs of using health services during the past two weeks;
5.) patient satisfaction with services and medicines (in-
cluding quality); 6.) views, knowledge, and attitudes on
health insurance and medicines use; and 7.) household
expenditure (monthly expenditure on food and non-food
consumption including medical expenditure on chronic
diseases, and annual expenditure on other specific matters
in the last year, including medical expenditure on
hospitalization or other specific doctor visits). The data in
the first 6 sections were collected for each individual
household member and the data in section 7 (household
expenditure) for each household. The questionnaire de-
sign was based on the one used for the Chinese National
Health Services Survey [33], which had been validated and
improved during four previous national surveys.
Sampling
The household surveys used a multi-stage stratified ran-
dom cluster sampling method. The urban districts were
divided into 2 (Baoji) or 3 groups (Hangzhou) based on
socio-economic level (good to poor). From each group,
one district was selected. In each district, 3 (in Baoji) or
2 sub-districts (in Hangzhou) were randomly selected in
order to pick 6 sub-districts in each city. Then, 3
Table 1 Basic socio-economic information of Hangzhou and Baoji in 2009
Hangzhou Baoji
Size of populationa 8,100,000 3,731,400








Number of health institutionsb 2687 903
Number of health workers per 1000 inhabitantsb 8.23 4.13
Number of hospital beds per 1000 inhabitantsb 5.89 4.23
a Data source: Hangzhou / Baoji Economic and Social Development Statistics Bulletin 2009
b Data source: Hangzhou / Baoji Health Development Statistics Bulletin 2009
GDP Gross Domestic Product
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communities (clusters) were sampled in each sub-district
(overall 18 clusters in each city), and 45 households sam-
pled in each community based on a random house-number
allocation. Only family members with household registra-
tion (known as ‘Hukou’ in China) were investigated to
ensure all included subjects were urban population. Due to
the different response rate in different communities, the
final number of households in each community was not
exactly 45. However, the total number of households was
guaranteed to exceed 800 in both cities.
Survey administration
An adequate number of investigators (> 20) selected
from local universities in the study cities and Fudan Uni-
versity were trained by researchers from the Fudan
School of Public Health (including first and second au-
thors of this study) to conduct the surveys. The house-
hold surveys were conducted in five consecutive years
(2009 to 2013) in order to continuously monitor services
utilization and health care expenditure. Households
could be censored due to moving, death, or ‘lost to
follow-up’. In such situations, new families with house-
hold numbers close to that of the censored households
were added to ensure the sample size of 800 households
was maintained. Therefore, the number of households
per year was not always exactly the same, but was main-
tained at more than 800 (Additional file 1: Table S1).
The head of the household was the main respondent of
the surveys. Parents answered questions relating to
children younger than 16 years of age. The survey data
were inputted by the investigators, and were checked by
a different investigator in the research team.
Health facility survey
In 2013, a health facility survey was conducted in Baoji
and Hangzhou hospitals. In each city, 20 hospitals were
identified. The proportion of primary, secondary, and
tertiary hospitals was different in the two cities based on
the local distribution of hospitals.
A structured questionnaire was designed to collect
hospital information over three years from the two cities
(2009, 2011, and 2012 for Baoji and 2009, 2011, and
2013 for Hangzhou). Key information on medicines use
included general information such as hospital scale,
revenue and spending, service amount delivered, and
medicines purchasing and utilization.
Data analysis
Availability, use, and affordability of medicines in the urban
populations were assessed. Details are provided below.
Medicines availability
To evaluate availability, data from sampled health facilities
was extracted from the health facility survey conducted in
2013. The number of different medicines stocked in the
facilities (including number of different essential medi-
cines, number of different antibiotics, and total number of
different medicines included in the basic health insurance
list) were analyzed to reflect the expected availability of
medicines in urban health facilities.
Medicines use
General information on survey subjects’ health needs dur-
ing the previous two weeks was extracted from the house-
hold survey (conducted from 2009 to 2013). Medicines
use during the previous two weeks was analyzed in terms
of percentage of patients taking medicines, the type of
medicines taken (traditional Chinese medicine versus
western medicine), and patients’ behavior and perception
of taking medicines (choice of institutions for prescription,
perception of dosage, and need). In addition, patients’ self-
reported views and attitudes regarding medicines use were
assessed. These view and attitude measures were only
collected in the household survey conducted in 2013.
Medicines affordability
Due to the lack of explicit data on annual medicine
expenditure, individual patient’s two-week OOP medi-
cine expenditures (extracted from the household survey)
were calculated to assess the economic burden of medi-
cine expenditure for the years 2009 to 2013. Individual
patient’s two-week expenditures for outpatient visits
were also analyzed and compared with medicine expen-
ditures. Patients’ two-week expenditures were collected
in the household survey using the medical records kept
by households, or self-reported information if there were
no records to track. In addition, to explore household
health-related economic burden, annual overall medical
expenditure per household (calculated by summing up
the annual chronic disease expenditure [monthly chronic
disease expenditure multiplied by 12] and the annual
specific medical expenditure) was compared with annual
total household non-food consumption expenditure col-
lected from the household surveys. Household income
was not chosen as the comparator because of the unreli-
ability of respondents’ self-reported income level [34].
All these expenditure measures were calculated for all 5
survey years in order to assess changing trends during
the survey period. Expenditures were reported in 2009
US dollars using the exchange rate between US dollar
(USD) and Chinese Yuan (CNY,) and adjusted for infla-
tion by the Chinese National Consumer Price Index
2010 to 2013 [35].
Impact of socio-economic setting
All outcomes (medicines availability, use, and affordabil-
ity) were calculated for Baoji and Hangzhou separately
to assess the impact of socio-economic setting.
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Statistics
Household survey data were entered into Epidata 3.1,
and health facility survey data into Excel 2013. Descrip-
tive and statistical analyses were performed using SPSS
18.0. Differences between UEBMI and URBMI / Baoji
and Hangzhou were compared using several statistical
tests. Expenditure data were reported using median, on
account of the skewed distribution. Categorical data
were compared using Chi-square tests. Continuous data
were assessed using Mann-Whitney U-tests for compari-
sons between the two insurance schemes and cities, and
using Kruskal-Wallis H-tests for comparisons between
the five survey years (due to the non-normally distrib-
uted data [e.g. health expenditure]). Data from the health
facility survey were not tested because of the low test
power introduced by the small sample size.
Results
Situational analysis
Hangzhou’s UEBMI benefit package includes a pooling
fund and a personal medical savings account. The pool-
ing fund covers hospitalization reimbursement, and the
personal account covers outpatient-visit reimbursement.
Deductible, co-payment, and ceiling practices are
employed as cost-sharing mechanisms to reduce pa-
tients’ moral hazard [36, 37]. All residents in the urban
area and not covered by UEBMI are able to join URBMI
on a voluntarily basis. URBMI does not have personal
savings account, but has a similar pooling fund with a
relatively higher co-payment by beneficiaries compared
with UEBMI (approximately 50% co-payment percentage
for URBMI versus 30% for UEBMI), in accordance with
its lower required beneficiaries’ contribution. Our study
indicates that there was a large gap between Hangzhou
and Baoji regarding insurance benefit. For those insured
by URBMI in Baoji, outpatient services were not cov-
ered, which led to a major burden for patients seeking
regular medical services. In both cities, the differences
between UEBMI and URBMI were only in the level of
contribution to insurance financing and benefits for
health services, while beneficiaries had the same accessi-
bility to health services in all health institutions in differ-
ent levels. A comparison between the two sample cities
regarding the latest basic medical insurance plan designs
is shown in Additional file 1: Table S2.
A national drug reimbursement list is issued to ensure
people’s basic health care demands are met, and to elimin-
ate unnecessary waste of resources through hierarchical
reimbursement levels for listed services or medicines. The
number of drugs on the 2010 Reimbursement Drug List is
shown in Table 2. Class A drugs are those that are neces-
sary for clinical use, and that demonstrate good effective-
ness and a low price; these are reimbursed 100% by basic
medical insurance. The list of Class A drugs is made by
the central government, and is identical nationwide.
Class B drugs are those that are optional for clinical
use, and with similar effectiveness but higher price
when compared with Class A drugs; these are partly re-
imbursed by basic medical insurance. The list of Class
B drugs is made by the municipal government, and the
reimbursement level differs based on municipal socio-
economic level (Table 2). The drugs on the NEML are
all included in Class A.
Medicines availability
The general information on the service capacity of the
investigated health facilities is shown in Additional file 1:
Table S3. The service capacity of primary health care
centers and tertiary hospitals in Hangzhou was greater
than for those in Baoji, while the service capacity of sec-
ondary hospitals was lower in Hangzhou. Since imple-
mentation of the National Essential Medicine Policy in
2009, primary health care centers are required to stock
and utilize medicines listed on the NEML — this list
includes about 300 medicines plus local additions [38].
As a result, there was a sharp decrease in the number of
different medicines (including antibiotics) stocked in pri-
mary health care centers in Hangzhou for the period
2009 to 2013 (Table 3), but the number of different
medicines (including antibiotics) increased for the period
2009 to 2012 in Baoji. Notably, the number of different
essential medicines in Baoji increased by 48.2% during
this period (from 166 to 246). Since the NEML applies
only to primary centers, the number of different medi-
cines grew slowly in secondary and tertiary hospitals in
both cities. However, a decreasing trend regarding num-
ber of antibiotics was found in secondary and tertiary
hospitals in both cities.
Medicines use
In Hangzhou, UEBMI beneficiaries accounted for 60% of
the household survey subjects; URBMI beneficiaries, less
than 30%. In Baoji, the percentages of UEBMI and
URBMI beneficiaries were both around 45% (Additional
file 1: Table S4). In Hangzhou and Baoji, 30.7% and
23.9% (p < 0.001) of subjects, respectively, reported sick-
ness in the two weeks before the 2013 survey (Table 4).
Approximately 90% of patients in both cities took
medicines during periods of sickness. Over half of those
patients used traditional Chinese medicine, including
both Chinese herbal medicine and Chinese patent medi-
cine (Hangzhou: 69.2%; Baoji: 56.2% [p < 0.001]). Ap-
proximately 10% of patients used western medicine
alone in the two sample cities (Table 4). Regarding
choice of institution for obtaining medicines, there was a
significant difference between the two sample cities. In
Hangzhou, the majority of patients (65.8%) obtained medi-
cines in primary health institutions; in Baoji, the majority
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(78.1%) obtained medicines in a pharmacy. In Hangzhou
and Baoji, 98.3% and 98.6% of patients respectively, knew
their medicine dosage (p = 0.396), and around 97% stated
that they followed doctor’s instructions when taking medi-
cines. There were more respondents stating that their med-
icines needs could be met in Baoji (96.6%) than in
Hangzhou (85.6%) (p < 0.001).
In both cities, the self-reported prevalence was higher
in UEBMI beneficiaries than in URBMI beneficiaries
(p < 0.001 in both cities). More URBMI beneficiaries than
UEBMI beneficiaries chose a pharmacy to fill a pres-
cription (p = 0.001 in Hangzhou; p < 0.001 in Baoji). In
Hangzhou, more URBMI beneficiaries than UEBMI
beneficiaries stated that their medicines needs had been
met (p = 0.035). Different insurance schemes did not
influence patient-reported dosage and prescription
compliance.
Medicines affordability
In general, median OOP medicine expenditure in the
two weeks before each survey was higher in Baoji than
in Hangzhou (Fig. 1). In both cities, and for both insur-
ance schemes, the medicine expenditure showed an
increasing trend from 2009 to 2013. The results did not
suggest that medicine expenditures were different be-
tween the insurance schemes (9 out of 10 p-values for
comparison between two schemes were larger than 0.05;
Additional file 1: Table S5). Compared with the average
expenditure on outpatient visits in the same past two
weeks, OOP medicine expenditure accounted for 26–51%
of outpatient expenditure in Hangzhou and 30 to 51%
in Baoji.
There was a significant increasing trend in house-
hold overall medical expenditures in both cities for
the period 2009 to 2013 (p < 0.001 for the 5 years of
comparison for both cities; expenditures were signifi-
cantly not all similar for the 5 years). The median an-
nual household overall medical expenditure was
higher in Hangzhou, and increased from 358 USD to
578 USD from 2009 to 2013, while it increased from
249 USD to 415 USD in Baoji during the same time
period. The average annual growth rate of medical
expenditure in 5 years (12.8% in Hangzhou; 13.6% in
Baoji) was much higher than the growth rate of
household non-food consumption expenditure (1.3% in
Hangzhou; 5.0% in Baoji).
Table 2 Reimbursement drug list in Hangzhou and Baoji in 2010












National-level 349 154 100% 791 833 –
Hangzhou 349 154 100% 866 951 80%, 97% and 99% based on drug types
Baoji 349 154 100% 983 961 85%
a Class A drugs are those necessary for clinical use, with good effectiveness and low price. The list of Class A drugs is made by the central government and is
identical nationwide
b Class B drugs are those optional for clinical use, with similar effectiveness but higher price compared with Class A drugs. The list of Class B drugs is made by the
municipal government
Table 3 Numbers of different medicines stocked in health facilities
Hangzhou Baoji
2009 2011 2013 2009 2011 2012
Primary health care centers Total number of different medicines 735 453 449 264 336 358












Number of different antibiotics 49 19 18 19 24 26
Secondary hospitals Total number of different medicines 813 832 849 635 643 638
Number of different medicines on Insurance Reimbursement List 770 797 809 554 596 655
Number of different antibiotics 59 53 38 39 36 35
Tertiary hospitals Total number of different medicines 930 957 992 730 750 876
Number of different medicines on Insurance Reimbursement List 808 841 913 677 716 805
Number of different antibiotics 66 51 51 68 47 48
a The National Essential Medicines Policy in China allows primary health care institutions to choose the medicines on the NEML and the additional provincial/
municipal list. Although primary institutions can only equip essential medicines on the two lists, they are not mandatorily required to equip all medicines on the
lists. So the numbers of NEML medicines were less than 307 in 2009 list, and rest of the stocked medicines were from the municipal list
NEML National Essential Medicines List
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Table 4 Medicines use during past two-week period in 2013




















UEBMI URBMI UEBMI URBMI





















Patients taking medicines 87.1% 86.5% 0.631 88.8% 91.7% 88.7% 0.078 89.9% 0.426
Type of medicines
WM 8.4% 11.3% 0.020 9.1% 12.0% 14.7% 0.046 12.8% < 0.001
TCM 67.6% 77.4% < 0.001 69.2% 55.0% 58.6% 0.069 56.4% < 0.001
Combination of WM & TCM 23.5% 11.3% < 0.001 21.3% 32.4% 26.8% 0.002 30.5% < 0.001
Not known 0.5% – – 0.4% 0.6% – – 0.4% 0.665
Type of institutions for medicines
Primary stationb 43.9% 39.8% 0.051 42.8% 8.2% 2.2% < 0.001 6.0% < 0.001
Primary centerb 23.3% 25.0% 0.369 23.0% 7.2% 2.9% < 0.001 5.5% < 0.001
Secondary & tertiary 20.7% 16.7% 0.018 19.9% 4.6% 6.0% 0.109 5.2% < 0.001
Private practice 0.3% 1.9% < 0.001 1.1% 3.2% 3.8% 0.408 3.5% < 0.001
Pharmacy 11.7% 16.7% 0.001 13.3% 74.8% 83.9% < 0.001 78.1% < 0.001
Knowing dosage 98.3% 97.2% 0.071 98.3% 98.9% 98.0% 0.101 98.6% 0.396
Following doctor’s instruction 96.4% 96.3% 0.892 96.1% 97.7% 97.5% 0.816 97.7% 0.001
Perception of whether medicines need was met
Met 84.3% 91.2% < 0.001 85.6% 96.3% 97.1% 0.366 96.6% < 0.001
Partly met 12.0% 7.9% 0.002 11.4% 3.3% 2.6% 0.357 3.0% < 0.001
Can’t be met 3.2% 0.9% 0.001 2.8% 0.2% – – 0.1% < 0.001
Not known 0.5% – – 0.4% 0.2% 0.3% 0.648 0.2% 0.133
a Total population included patients with all types of insurances, thus the number of patients in total population were larger than the sum of patient numbers
from UEBMI and URBMI
b Primary health care station: non-profit primary medical and public health service institution that serves for one community, affiliated to primary health care cen-
ter; Primary health care center: non-profit primary medical and public health service institution that usually serves for one sub-district
TCM traditional Chinese medicine, UEBMI Urban employee basic medical insurance, URBMI Urban resident basic medical insurance, WM western medicine
Fig. 1 Comparison of OOP medicine expenditures in the two weeks before each survey (median). Abbreviations: OOP, out-of-pocket; UEBMI:
Urban employee basic medical insurance; URBMI: Urban resident basic medical insurance
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Discussion
This study analyzed medicines availability, use, and afford-
ability in urban China following the implementation of
the Health Care System Reform 2009 and UHC. To our
knowledge, there are no empirical studies using longitu-
dinal data to assess medicines use following UHC imple-
mentation in China. Our results show that the availability
of medicines in hospitals, the use of medicines, and the
affordability of medicines varied between the two sample
cities and health insurance schemes for the period of
study. Different types of urban basic health insurance (i.e.
UEBMI and URBMI) influenced patients’ behavior when
seeking health services and medicines (e.g. choice of insti-
tutions for obtaining medicines), but did not show clear
impact on medicine expenditures. The results also show
that patients’ OOP medicine expenditures increased sig-
nificantly over the period 2009 to 2013, and that house-
hold overall medical expenditure increased much greater
than non-food consumption expenditure.
Medicines availability
After implementation of UHC in China, the availability of
medicines in health facilities was improved. A previous
study showed greater availability of low-priced generics in
primary health care facilities [26]. The present study dem-
onstrated improved availability of essential drugs and im-
proved drug stock in primary health facilities for the study
period. The National Essential Medicine Policy requires
primary health facilities to stock and prescribe essential
medicines, and regulates medicine bidding and purchasing
strictly. Our results showed that the proportion of essen-
tial medicines increased from 37% in 2009 to 49% in 2013.
After the establishment of UHC, the government acceler-
ated the development of primary institutions and in-
creased their service capacities. However, the socio-
economic development level was still a major determinant
for medicine availability. Health care facilities in cities with
higher socio-economic level, (e.g. Hangzhou) were allo-
cated more medicines overall.
Medicines use
Under the national guidance for developing UHC, local
health insurance authorities were encouraged to imple-
ment municipality-wide health insurance schemes
tailored to local socio-economic situations. This
decentralization arrangement has led to great differences
in health insurance schemes, benefit packages, and pa-
tients’ health-related financial burden [39]. Even within
the same national Chinese health insurance schemes,
there were major differences in local implementation
regarding service coverage for outpatient and inpatient
care and availability of medicines, mainly due to differ-
ent levels of socio-economic development. In Hangzhou
(high socio-economic level), URBMI covered outpatient
visits — this was not the case in Baoji. This difference in
insurance schemes might have influenced patients’
medicines use: for example, UEBMI beneficiaries were
more likely to take medicines than URBMI beneficiaries
due to the higher level of health insurance benefits.
These results are consistent with previous evidence that
indicates that differences in local UEBMI and URBMI
schemes may increase inequities in the use of outpatient
services — for example, that high-income populations
utilize outpatient services more than low-income popu-
lations [40]. However, URBMI has positively increased
the use of inpatient services [41, 42]. In general, and des-
pite the potential inequity introduced by different health
insurance schemes, our results showed that urban popu-
lation were mostly satisfied with their medicines use
based on their self-reported perception.
Medicines affordability
Although studies have shown that encouraging the use
of essential medicines is effective in curtailing prescrip-
tion medicines costs [20], the affordability of medicines
is still a challenge in China [25]. Medicines expenditure
increased significantly during the 5-year study period,
and the cost of medicines accounted for a major part of
outpatient-visit expenditure. Our health facility survey
showed that medicines revenue, as a proportion of total
revenue, for health institutions was 50% in Hangzhou
and > 30% in Baoji. The percentage contribution of house-
hold overall medical expenditure to total non-food con-
sumption expenditure was significantly higher in the
sample cities than in high-income countries (12.8% in
Hangzhou and 13.6% in Baoji versus around 8% in U.S.)
[43]. The reported growth rate of annual household med-
ical expenditure was much higher than annual household
consumption expenditure, which reflected that the grow-
ing trend of increasing medical costs was still a financial
threat to Chinese urban residents — especially those at a
lower socio-economic level. The health insurance schemes
didn’t seem to influence medicine affordability; there were
no significant disparities between medicine expenditure in
UEBMI and URBMI schemes. The Chinese government
still has a long way to go when it comes to reducing the
medical-economic burden and changing the perception
that seeing a doctor is expensive.
Limitations
The main limitation of this study was the difficulty in in-
ferring causality between the implementation of UHC
and differences in medicines availability, use, and afford-
ability. The UHC scheme, and the supporting policies that
were implemented following the Health Care System
Reform in 2009, were rapidly developed and subsequently
adjusted. Thus, changes in the availability, use, and afford-
ability of medicines may not be directly explained by any
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one single policy. Monitoring practices, and a continuous
analysis of China’s health system, need to be promoted to
encourage further research and assessment. Large scale
electronic databases, including administrative or insurance
claims databases, could be developed — ideally quickly,
preferably to a standard protocol — to provide continuous
evidence gathered from across the country. Other limita-
tions of this study were mainly related to the data collec-
tion in the household surveys. Although randomization
was conducted as strictly as was possible when sampling
communities, there were still factors that influenced selec-
tion bias in the surveys. The inclusion of households was
dependent on respondents’ willingness to participate in
the surveys. The elderly people, and highly-educated
people, were more cooperative. The difference in data
from included subjects and those who refused to partici-
pate in surveys was difficult to evaluate. Recall bias might
also influence the accuracy of the self-reported medicine-
use data and the income and expenditure data. For
example, those who were familiar with their own medical
condition and used medicines regularly might report more
accurate medicine-use data, and respondents’ perceptions
of privacy and money might influence the accuracy of in-
come and expenditure data.
Conclusions
In conclusion, after China’s Health Care System Reform
in 2009 and the accompanying implementation of UHC,
the availability and use of medicines has improved —
but affordability of medicines is still a concern for policy
makers. Improvements in policies focusing on narrowing
the gap between health insurance schemes and regulating
medicine allocation and use are highly recommended.
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